Viewd By : 136 visitors
The United States Department of Health and Human Services give French drug maker Sanofi multinational pharmaceutical company nearly $43 million to develop a Zika Vaccine to prevent the relevant infection.
Zika is Genus Flavivirus species which include West Nile virus, dengue, and yellow fever is mainly spread by the Aedes aegypti mosquito’s bite.
The French drug maker said that, “The funding from the HHS' Biomedical Advanced Research and Development Authority (BARDA) will be utilized for mid-stage trials and expected to begin in the first half of 2018.”
In addition, the funding sprints over June 2022, but if the data is positive, then fund includes up to $130.45 million for late-stage trials, which is crucial for final or eventual approval.
According to the survey, it is predicted that hundreds of thousands of Americans have been infected with Zika Virus. Plus, it was also detected in Brazil and some parts of Asia last year where most people experienced only a mild illness or no symptoms.
Zika virus can pierce the pregnant woman's womb and lead to a crippling birth defect which is known as microcephaly. In adults, it has been associated with Guillain-Barre syndrome, a form of temporary paralysis.
Sanofi Pasteur has already several vaccines approved for others flaviviruses, like yellow fever, dengue, and Japanese encephalitis. Now they are looking forward to developing a vaccine against the Zika virus to cure this infectious disease.
However, at the beginning of 2016, Biotic Healthcare had covered the outbreak of Zika Virus. Click here An OutBreak of Zika Virus – An Emerging Health Threat Declared by WHO to check the Zika Virus: Symptoms, Risk, Treatment & Prevention in detail.
Biotic healthcare an ISO 9001-2008 Certified Pharmaceutical Company and is one of the fastest growing PCD Pharma company with a vision and potential to cover the global market of the healthcare industry. We always believe in sharing healthcare tips/news that helps in saving someone important life.